That's great news, and I would have liked to hear more about this patent for MSC treatments developed by others. For instance, if this patent can be used to monitor Mesoblast (ASX:MSB) efficiency, this could lead to a partnership with the leader in this field, and therefore bring attention to RGS from MSB investors.
Ann: Australian Biomarker Patent Allowed, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.368M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 52731 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 24 | 1 |
View Market Depth
| Last trade - 16.12pm 16/10/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable